Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Adherex Technologies, Inc. |
---|---|
Information provided by: | Adherex Technologies, Inc. |
ClinicalTrials.gov Identifier: | NCT00265057 |
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.
Condition | Intervention | Phase |
---|---|---|
Neoplasms |
Drug: ADH -1 (Exherin™) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Italy | |
Istituto Nazionale per lo Studio e la Cura dei Tumori | |
Milan, Italy, 20133 | |
Instituto Europeo di Oncologia | |
Milan, Italy, 20141 | |
Switzerland | |
Istituto Oncologico della Svizzera Italiana | |
Bellinzona, Switzerland, 6500 |
Study ID Numbers: | Adherex Protocol # AHX-01-004 |
Study First Received: | December 13, 2005 |
Last Updated: | November 8, 2007 |
ClinicalTrials.gov Identifier: | NCT00265057 |
Health Authority: | United States: Food and Drug Administration |
Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; |
Antineoplastic Agents; Cadherins; Non-Small-Cell Lung Carcinoma; Ovarian Cancer |
Ovarian cancer Signs and Symptoms Non-small cell lung cancer Ovarian Neoplasms |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma |
Neoplasms |